Five states fail prostate cancer report card

"This is the first data to show that antegrade instillation of UGN-101 had lower ureteral stricture rates compared [with] retrograde approaches,” said Josh Gottlieb, DO.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

The phase 3 PROpel trial provided the primary supporting data for the approval.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

Dr. Avi Baskin and Dr. Katsuto Shinohara were honored for their extraordinary work.

Outstanding early-career researchers acknowledged for novel studies to enhance the well-being of patients with bladder cancer.